Raydiant Oximetry Oversubscribes Series A $7.5 Million Extension Round Raydiant Oximetry, a clinical-stage medical device company, has oversubscribed a $7.5 million Series A3 extension round.

Raydiant Oximetry Secures FDA Approval for Lumerah Investigational Device Exemption (IDE) Study The FDA has approved the Investigational Device Exemption (IDE) of Lumerah for an Early Feasibility Study (EFS) of pregnant women during labor and delivery